Table 4.
Comparison between Responder Group and Non-responder Group at Baseline.
| Responder group (n=90) | Non-responder group (n=10) | p value | |
|---|---|---|---|
| Age (yr) | 67.3±1.3 69.0 [62.8-76.0] |
69.3±2.9 70.5 [60.5-77.3] |
0.7879 |
| Number of male/female | 6/84 | 1/9 | 0.5333 |
| Postmenopausal (%) | 77 (91.7) | 9 (100) | 0.9999 |
| Body mass index (kg/m2) | 20.8±0.3 20.3 [18.6-22.7] |
20.5±1.0 19.5 [18.0-22.7] |
0.6202 |
| Prednisolone usage (%) | 61 (67.8) | 7 (70.0) | 0.9999 |
| Daily prednisolone-equivalent dose (mg/day) | 6.1±0.6 5.0 [3.0-8.0] |
13.6±5.0 6.0 [5.0-20.0] |
0.0666 |
| Bone mineral density (g/cm2) | 0.75±0.01 0.76 [0.67-0.84] |
0.78±0.04 0.78 [0.67-0.81] |
0.8763 |
| Diagnosis, no. (%) | |||
| Rheumatoid arthritis | 47 (52.2) | 4 (40) | 0.5208 |
| Systemic lupus erythematosus | 13 (14.4) | 1 (10) | 0.9999 |
| Polymyalgia rheumatica | 10 (11.1) | 1 (10) | 0.9999 |
| Polymyositis/dermyositis | 3 (3.3) | 2 (20) | 0.0628 |
| Mixed connected tissue disease | 4 (4.4) | 0 (0) | 0.9999 |
| Sjögren’s syndrome | 4 (4.4) | 0 (0) | 0.9999 |
| Vasculitis syndrome | 3 (3.3) | 1 (10) | 0.3484 |
| Systemic scleroderma | 3 (3.3) | 0 (0) | 0.9999 |
| Others | 3 (3.3) | 1 (10) | 0.3484 |
| Pre-denosumab treatment, no. (%) | |||
| Bisphosphonates | 53 (58.9) | 7 (70) | 0.7357 |
| Teriparatide | 9 (10) | 1 (10) | 0.9999 |
| Vitamin D | 8 (88.9) | 0 (0) | 0.9999 |
| Vitamin K | 3 (33.3) | 0 (0) | 0.9999 |
| SERM | 2 (2.2) | 1 (10) | 0.2735 |
| Baseline of bone turnover markers | |||
| NTx (nmolBCE/L) | 16.3±0.7 14.7 [11.9-19.5] |
17.3±1.8 17.4 [12.8-22.5] |
0.3877 |
| TRACP-5b (mU/dL) | 271.3±18.5 251.0 [156.5-347.8] |
194.3±36.3 189.0 [88.0-278.5] |
0.1572 |
| P1NP (µg/L) | 34.1±3.4 25.4 [17.7-41.8] |
27.9±3.7 28.3 [18.1-39.3] |
0.9465 |
| BAP (µg/L) | 14.1±1.3 11.6 [8.9-15.6] |
9.3±0.7 9.6 [7.2-11.3] |
0.0499 |
| OC (ng/mL) | 7.2±0.5 6.0 [4.0-8.2] |
5.8±1.0 5.6 [3.5-8.1] |
0.5044 |
| Change of bone turnover markers (%) | |||
| Δ NTx | -20.4±3.4 -25.6 [-39.1- -4.6] |
-1.5±18.7 -30.3 [-46.1-61.1] |
0.7736 |
| Δ TRACP-5b | -45.2±4.8 -59.0 [-72.7- -27.5] |
16.5±29.5 10.5 [-64.4- 69.4] |
0.0454 |
| Δ P1NP | -33.1±5.2 -43.4 [-68.2- -15.9] |
8.0±27.5 -21.0 [-62.7- 104.1] |
0.2281 |
| Δ BAP | -15.5±11.3 -27.9 [-44.4- -13.6] |
-4.4±10.7 -13.0 [-29.5- 25.1] |
0.0457 |
| Δ OC | -3.4±13.3 -28.6 [-46.7- 3.3] |
63.5±47.8 -5.7 [-48.6- 189.1] |
0.1914 |
SERM: selective estrogen receptor modulators, NTx: N-telopeptide crosslinked of type I collagen, TRACP-5b: tartrate-resistant acid phosphatase isoform 5b, P1NP: procollagen type I N-terminal peptide, BAP: bone alkaline phosphatase, OC: osteocalcin, Δ: the rate of change during 12 months